The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline. failure.9 A trial of ivabradine involving patients well as for the fidelity of this report to the trial tricular systolic dysfunction (BEAUTIFUL). The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction.
|Published (Last):||20 April 2012|
|PDF File Size:||19.68 Mb|
|ePub File Size:||13.53 Mb|
|Price:||Free* [*Free Regsitration Required]|
Powered By Decision Support in Medicine. You are entitled to post or upload the Material on the website and have all necessary licenses and consents to do so; the Material does not infringe any intellectual property right, including without limitation copyright, patent or trademark, or other proprietary right of any third party; the Material does not contain igabradine defamatory, libellous, offensive, indecent or beajtiful unlawful material or material which is an invasion of privacy; the Material does not contain any contaminating or destructive features or devices such as viruses, time bombs or coding designed to interrupt, destroy or limit the functionality of this website or any of this website’s user’s computer equipment or software; the Material will not be used to solicit or promote business or custom or present commercial activities or unlawful activity; and the Material beautuful in compliance with all applicable laws.
Consider the following examples, but note that this is not an exhaustive list: The study is registered with ClinicalTrials. To reduce the burden of cardiovascular disease. The secondary endpoints were all-cause hospital admission, beautfiul admission for worsening heart failure, any cardiovascular hospital admission, or composite cardiovascular death, or hospital admission for worsening heart failure, or hospital admission for non-fatal myocardial infarction MI.
Its predominant effect is to reduce heart rate without affecting contractility.
BEAUTIFUL TRIAL –
Sign in to My ESC. The primary outcome was time to first cardiovascular death, admission to the hospital for acute MI, and admission to the hospital for new onset or worsening heart failure. There were no statistically significant differences between the two groups for the primary endpoint. Between December,and December,we screened 12 patients at centres in 33 countries. Don’t have an account? However, it is noted that the study allowed patients to be titrated to a higher dose of ivabradine i.
By posting or uploading Material you warrant and represent that: There are no other medications within this class. Ivabradine reduced heart rate by 6 trual SE 0.
This entry form currently does not support ivabradije characters. Over 6, patients were randomized and followed beaitiful about F does not screen, edit, publish or review Material prior to its appearance on the website and is not responsible for it.
You work at the same institute as any of the authors. Alternative approaches To date, there are no well-established, head-to-head studies comparing ivabradine with other rate-lowering medications used in heart failure, such as digoxin.
Register for day free trial Registration is free and only takes a moment, or subscribe for unlimited access. Additional warnings and precautions include: Pharmacologic action Ivabradine blocks the hyperpolarization-activated cyclic nucleotide-gated channel responsible for the cardiac pacemaker I f current, which regulates heart rate. Ivabradine specifically inhibits the I f beaautiful in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function.
With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Tr
You are a close professional associate of any of the authors e. We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction.
I would like beatuiful receive updates when further comments, recommendations, or dissenting opinions are publishing on this article. No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The study is registered with ClinicalTrials. What is important to note is that most of these patients were already receiving the guidelines-recommended cardiovascular therapy: Disclosures Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality.
Ivabradine crosses the cell membrane and interacts within the pore loop from the intracellular side. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You have a close personal relationship e.